Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1303-1310

  Fedier, Andre ^a   Erdmann, Ruediger ^a   Boulikas, Teni ^b   Fink, Daniel ^a  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^b Regulon Inc   (United States)

Author keywords

Akt; Akt inhibitor LY294005; DNA mismatch repair; Platinum drug resistance

Indexed keywords

1L 6 HYDROXYMETHYL CHIRO INOSITOL 2(R) 2 O METHYL 3 O OCTADECYLCARBONATE; 1L-6-HYDROXYMETHYL-CHIRO-INOSITOL 2(R)-2-O-METHYL-3-O-OCTADECYLCARBONATE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CHROMONE DERIVATIVE; CISPLATIN; DOCETAXEL; DRUG DERIVATIVE; INOSITOL; MLH1 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; NUCLEAR PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; TAXOID;

ADENOCARCINOMA; ARTICLE; BASE MISPAIRING; CELL CULTURE; COLORECTAL TUMOR; DNA REPAIR; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; CARRIER PROTEINS; CHROMONES; CISPLATIN; COLORECTAL NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; INOSITOL; MORPHOLINES; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 39049183757     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1303     Document Type: Article

References (40)

1. Modrich P and Lahue R: Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 65: 101-133, 1996. (Pubitemid 26250606)
2. Jiricny J: Replication errors: cha(lle)nging the genome. EMBO J 17: 6427-6436, 1998.
3. Kolodner RD and Marsischky GT: Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 9: 89-96, 1999.
4. Fishel R and Kolodner RD: Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382-395, 1995.
5. Peltomaki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21: 1174-1179, 2003. (Pubitemid 46594150)
6. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR and Koi M: Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55: 3721-3725, 1995.
7. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341, 1998.
8. Branch P, Hampson R and Karran P: DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55: 2304-2309, 1995.
9. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996. (Pubitemid 26374423)
10. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M and Mace R: Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273: 1109-1111, 1996.
11. Fedier A, Fowst C, Tursi J, Geroni C, Haller U, Marchini S and Fink D: Brostallicin (PNU-166196) - a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br J Cancer 89: 1559-1565, 2003.
12. Fedier A, Schwarz VA, Walt H, Delli Carpini R, Haller U and Fink D: Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 93: 571-576, 2001.
13. Fedier A, Poyet C, Perucchini D, Boulikas T and Fink D: MLH1-deficient tumour cells are resistant to lipoplatin but retain sensitivity to lipoxal. Anticancer Drugs 17: 315-323, 2006.
14. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB and Brown R: Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 18: 87-93, 2000.
15. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS and Howell SB: Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6: 1415-1421, 2000.
16. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A and Hay N: Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22: 7831-7841, 2002.
17. Coffer PJ, Jin J and Woodgett JR: Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335: 1-13, 1998.
18. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
19. Hanada M, Feng J and Hemmings BA: Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 1697: 3-16, 2004.
20. King FW, Skeen J, Hay N and Shtivelman E: Inhibition of Chk1 by activated PKB/Akt. Cell Cycle 3: 634-637, 2004.
21. Hirose Y, Katayama M, Mirzoeva OK, Berger MS and Pieper RO: Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65: 4861-4869, 2005.
22. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
23. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK and Cheng JQ: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412, 2004.
24. Testa JR and Bellacosa A: AKT plays a central role in tumori-genesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
25. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV and Cheng JQ: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10: 975-987, 2005.
26. Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper RO, Stokoe D and Haas-Kogan DA: PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71: 215-222, 2005.
27. Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G and Kozikowski AP: 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 43: 3045-3051, 2000.
28. Tsurutani J, West KA, Sayyah J, Gills JJ and Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65: 8423-8432, 2005.
29. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R and Cocco L: A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17: 1794-1805, 2003.
30. Viniegra JG, Losa JH, Sanchez-Arevalo VJ, Parada Cobo C, Soria VM, Ramon y Cajal S and Sanchez-Prieto R: Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin. Oncogene 21: 7131-7136, 2002.
31. Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C, Broggini M, Iacobelli S, Potter BV, Innocenti P and Falasca M: Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res 65: 8339-8349, 2005.
32. Hu H, Jiang C, Li G and Lu J: PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 26: 1374-1381, 2005. (Pubitemid 41417880)
33. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, De Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q and Giranda VL: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4: 977-986, 2005.
34. Viniegra JG, Martinez N, Modirassari P, Losa JH, Parada Cobo C, Lobo VJ, Luquero CI, Alvarez-Vallina L, Ramon y Cajal S, Rojas JM and Sanchez-Prieto R: Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 280: 4029-4036, 2005.
35. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Lavin MF and Esumi H: Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J Biol Chem 278: 48-53, 2003.
36. Altiok S, Batt D, Altiok N, Papautsky A, Downward J, Roberts TM and Avraham H: Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem 274: 32274-32278, 1999.
37. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ and Qin J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14: 927-939, 2000.
38. Boulikas T: Low toxicity and anticancer activity of a novel liposomal Cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 12: 3-12, 2004.
39. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC and Testa JR: The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60: 5390-5394, 2000.
40. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H and Komuro I: Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J 23: 212-220, 2004.